- Home
- CMP vs GHRS Comparison
CMP vs GHRS Comparison
Compare CMP & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMP | GHRS |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 947.2M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CMP | GHRS |
|---|---|---|
| Price | $30.49 | $22.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $21.50 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 708.5K | 193.2K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | $40.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.40 | $10.96 |
| 52 Week High | $32.39 | $24.66 |
Technical Indicators
Market Signals| Indicator | CMP | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 61.36 |
| Support Level | $20.83 | $12.65 |
| Resistance Level | $32.39 | $22.88 |
| Average True Range (ATR) | 2.00 | 1.49 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 78.25 | 58.59 |
Price Performance
Historical ComparisonAbout CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.